원문정보
초록
영어
Antibodies and related products are the fastest growing class of therapeutic agents. The currently marketed antibody-based drugs have been approved not only to treat diseases affecting large numbers of patients (such as cancer and autoimmune diseases) but also for more specialized indications (such as orphan diseases). Antibodies have been the highest earning category of all biological drugs; several monoclonal antibodies generated multi billion dollar revenues including Rituxan, Herceptin and Avastin from Genentech. In this presentation, I will presentation our strategies of selecting and optimizing potential therapeutic antibodies at Genentech. Specific case studies will be provided for engineering specific and potent antibodies to dissect complex biological systems, and development of therapeutic antibodies with good CMC properties for clinical trials.